Associations between early tumor shrinkage/depth of response and survival from the ARCAD database
Early tumor shrinkage and depth of response serve as valuable prognostic markers in RAS wild-type metastatic CRC, particularly for patients treated with anti-EGFR antibodies. These findings highlight the potential role of early tumor shrinkage and depth of response in guiding treatment strategies and improving outcomes for patients with CRC.
Authors
- Yoshihiko Maehara (ORCID: https://orcid.org/0000-0002-1532-3537)
- Cornelis J. A. Punt (ORCID: https://orcid.org/0000-0003-4196-4896)
- Toshihiro Misumi (ORCID: https://orcid.org/0000-0001-8339-2895)
- Alan P. Venook (ORCID: https://orcid.org/0000-0001-9749-6548)
- Kentaro Yamazaki (ORCID: https://orcid.org/0000-0001-6269-9345)
- Tomomi Nishikawa
- Hideaki Bando (ORCID: https://orcid.org/0000-0001-5041-2765)
- Heinz‐Josef Lenz (ORCID: https://orcid.org/0000-0003-2178-9568)
- Qian Shi (ORCID: https://orcid.org/0000-0002-4640-8832)
- Yuriko Takeda (ORCID: https://orcid.org/0000-0002-0459-493X)
- Masashi Wakabayashi (ORCID: https://orcid.org/0009-0001-6368-5671)
- Miriam Koopman (ORCID: https://orcid.org/0000-0003-1550-1978)
- Takayuki Yoshino (ORCID: https://orcid.org/0000-0002-0489-4756)
- Eiji Oki (ORCID: https://orcid.org/0000-0002-9763-9366)
- Carsten Bokemeyer (ORCID: https://orcid.org/0000-0001-6071-7810)
- Thierry André (ORCID: https://orcid.org/0000-0002-5103-7095)
- Eric Van Cutsem (ORCID: https://orcid.org/0000-0002-6372-1230)
- Aimery de Gramont
- Jean‐Yves Douillard (ORCID: https://orcid.org/0000-0002-6540-7333)
Institutions
- Kyushu University (JP)
- Universität Hamburg (DE)
- University of California, San Francisco (US)
- Keck Hospital of USC (US)
- University Medical Center Utrecht (NL)
- Sorbonne Université (FR)
- Shizuoka Cancer Center (JP)
- Integrated Oncology (United States) (US)
- Hôpital Saint-Antoine (FR)
- University Medical Center Hamburg-Eppendorf (DE)
- Mayo Clinic in Arizona (US)
- Centre de Recherche Saint-Antoine (FR)
- Kyushu Central Hospital of the Mutual Aid Association of Public School Teachers (JP)
- Institut Hospitalier Franco Britannique (FR)
- National Cancer Center Hospital East (JP)
- Mayo Clinic in Florida (US)
- University of San Francisco (US)
- Nantes Université (FR)
- KU Leuven (BE)
Publication Details
- Journal
- JNCI Cancer Spectrum
- Published
- 2025-04-25
- DOI
- https://doi.org/10.1093/jncics/pkaf042
- Primary Topic
- Colorectal Cancer Treatments and Studies
- Type
- article
- Field-Weighted Citation Impact
- 0.00
Funders
- Amgen
- Bristol-Myers Squibb
- Eli Lilly and Company
- Pfizer
- AstraZeneca
- GlaxoSmithKline
- Sanofi
- Gilead Sciences
- Regeneron Pharmaceuticals
- Taiho Pharmaceutical
- Les Laboratories Pierre Fabre
- Nihon Medi-Physics
- Mirati Therapeutics
- Boehringer Ingelheim Japan
- Seagen
- Bayer HealthCare
- Eisai
- Servier
- Yakult Honsha
- Ono Pharmaceutical
- Nordic Pharma Group
- Sirtex Medical
- Aptitude Health
- National Institutes of Health
- Genentech
- Pfizer Japan
- Chugai Pharmaceutical
- Eli Lilly Japan
- Bayer Yakuhin
- National Cancer Institute
- Daiichi Sankyo Europe